Navigation Links
Leading HIV researchers to collaborate on vaccine development
Date:4/15/2008

DURHAM, NC, and NEW YORK, NY Two global research organizations dedicated to designing a vaccine against HIV the International AIDS Vaccine Initiative (IAVI), and the Center for HIV/AIDS Vaccine Immunology (CHAVI) have signed an agreement to work together to address major biological questions that have slowed development of a safe, effective and affordable AIDS vaccine.

Solving the HIV vaccine puzzle is a scientific challenge that can only be solved through fundamental and applied research, collaboration and transparency. The work that will be done by IAVI, CHAVI and their networks of partners will rapidly enhance our understanding of HIV and help lay the groundwork for new vaccine approaches, says Dr. Barton Haynes, CHAVI director and professor of medicine at Duke University Medical Center.

There are approximately 33 million people around the world living with HIV, the virus that causes AIDS. Scientists have tested multiple vaccine candidates in early phase trials, but only two have been fully tested in efficacy trials and neither has been found effective in preventing HIV infection or lowering the viral load in patients who subsequently encountered HIV and became infected.

We are committed to the discovery of an effective vaccine, particularly for regions hardest hit by the epidemic, says Dr. Wayne Koff, senior vice president of research and development at IAVI. We are hoping that the synergy of shared investigation will yield insight into novel solutions that will advance AIDS vaccine discovery.

The shared CHAVI/IAVI research mission will focus on four key areas that will help inform the design of new and improved vaccine candidates:

  • Identification and full-length genetic sequencing of newly transmitted viruses

  • Clarifying the impact of human genetics on the control of HIV infection

  • Collaborative immunological studies that could shed light on why some people who are exposed to HIV do not develop AIDS

  • Development of standardized methods to sample tissues from mucosal surfaces in the body, where HIV initially establishes infection.

Investigators supported by both organizations are especially interested in further understanding what happens in the very earliest post-infection stage of HIV infection, especially within the bodys T cells, a class of white blood cells that normally fight off foreign invaders like bacteria and viruses. One of the goals of this work will be to identify any genetic variations linked to the strength of the immune response at the site of initial infection. CHAVI and IAVI hope that by sharing samples, reagents, databases and laboratories and by launching parallel studies, they will be able to speed up discoveries about this critical phase of the disease.

Each partner to the agreement will contribute unique resources. For example, CHAVI supports high-throughput sequencing technology that can reveal tiny mutations in the ever-changing virus, but which require large numbers of HIV samples in order to identify variations that are meaningful. Through its network of clinical research centers and immunological laboratories around the world, IAVI and its partners have developed a number of tests to evaluate human immune responses to HIV and to potential vaccine candidates, information that can help researchers refine and improve any candidate that shows promise. By pooling technologies, protocols and access to samples, the IAVI/CHAVI collaboration aims to extract maximum information to help accelerate the development of a safe and effective AIDS vaccine.

As an African clinical investigator and the leader of the scientific steering committee that oversees the IAVI-supported study of acute HIV infection, I am pleased to be collaborating with IAVI and CHAVI. It is critical to investigate the influence of genetic diversity of HIV as well as the variety of human immune responses to HIV among populations that are hardest hit by the epidemic, said Dr. Pontiano Kaleebu, assistant director and a Principal Investigator at the Uganda Virus Research Institute.

Now, more than ever, we need to understand the complexities of HIV and the genes that control the human immune response to it, says Dr. Alan Bernstein, recently appointed as the first executive director of the Global HIV/AIDS Vaccine Enterprise. The Enterprise was established to accelerate development of a safe and effective HIV vaccine through encouraging collaboration within the HIV vaccine research field. This new collaboration holds great promise in accelerating our basic understanding of HIV and will form the necessary underpinnings needed to develop a vaccine, Bernstein added.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-684-4148
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Leading experts investigate Shaken Baby Syndrome
2. Unstable Economy Leading to Executive Stress
3. Leading Life Sciences Company Installs SafeMedias Network Security Management Appliance to Prevent Illegal Peer to Peer (P2P) File Sharing
4. Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform
5. Europes Leading Premium Appliance Brand Taps Americas Most Stylish, Multi-Tasking Mom to Launch New Appliance Line in North America
6. Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand
7. New Welsh Self-Test to Cure Glaucoma, the Leading Cause of Preventable Blindness
8. Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps
9. AutismOnline.org Partners With Leading Health Communications Firm for Support
10. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
11. Leading Health Groups Applaud Continued Efforts to Protect Public Health by Ending So-Called Theatrical Productions in Bars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: